Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

Cue Biopharma (NASDAQ:CUE) announced its earnings results on Friday. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45), FiscalAI reports. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Cue Biopharma Stock Up 10.0%

Shares of Cue Biopharma stock traded up $3.12 during trading on Friday, hitting $34.20. The company’s stock had a trading volume of 157,074 shares, compared to its average volume of 195,652. The company has a fifty day simple moving average of $29.50 and a two-hundred day simple moving average of $147.28. Cue Biopharma has a 52 week low of $4.97 and a 52 week high of $45.50.

Institutional Trading of Cue Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Boothbay Fund Management LLC increased its holdings in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares in the last quarter. Stifel Financial Corp raised its holdings in Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Cue Biopharma in the third quarter worth $62,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after buying an additional 73,000 shares in the last quarter. 35.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of Cue Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.